Benitec Biopharma Inc.
BNTC
$-0.76
Change (1 day)
$13.29
Year High
$2.69
Year Low
Categories
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
P/B ratio for Benitec Biopharma Inc. (BNTC)
P/B ratio as of 2024: 0.62
According to Benitec Biopharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.62. At the end of 2023 the company had a P/B ratio of 27.85.
P/B ratio history for Benitec Biopharma Inc. from 2013 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 0.62 |
| 2023 | 27.85 |
| 2022 | 3.29 |
| 2021 | 0.91 |
| 2020 | 0.79 |
| 2019 | 0.83 |
| 2018 | 2.05 |
| 2017 | 1.28 |
| 2016 | 0.86 |
| 2015 | 4.39 |
| 2014 | 4.69 |
| 2013 | 0.93 |